Alloplex Biotherapeutics has identified cancer tumor types responsive to its lead technology platform, SUPLEXA, in a single-agent study.
Topic: Research News
-
March 27, 2024
Alloplex set to validate crucial immunotherapy hypothesis and expands corporate structure with advisory panel.
Read More -
April 29, 2022
Alloplex Biotherapeutics announces opening of first clinical trial site
Phase 1 trial of autologous SUPLEXA cell immunotherapy, commences in Adelaide South Australia
Alloplex Biotherapeutics announced today the site opening for its first-in-human clinical trial of SUPLEXA. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived, from patient peripheral blood mononuclear cells. This Phase 1 is a first-in-human, open-label single agent b...
Read More -
April 11, 2022
Alloplex SUPLEXA cells resist immunosuppressive action of two inhibitory cytokines typically found in tumor microenvironment
On April 12, 2022, Jim Lederer, MD, Chief Scientific Officer of Alloplex Biotherapeutics Inc. will present a Poster at the AACR 2022 Annual Meeting in New Orleans, Louisiana: AACR Abstract: IL-10/TGFβ Abstract Control Number: 3599 Title: Interleukin-10 and transforming growth factor-beta do not suppress tumor killing...
Read More -
November 15, 2021
Alloplex presents poster describing novel tumor-killing cells at SITC 2021 Conference
Non-engineered SUPLEXA cells demonstrate potent activity against patient-derived cancer organoids in vitro.
Today Alloplex Biotherapeutics released details of its abstract entitled Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells presented at SITC 2021. Alloplex’s abstract shows that the organization can generate tumor-killing cells from PBMCs using a clinical grade manufacturing process for SU...
Read More